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ABSTRACT 
Objective: To investigate brain structural connectivity in relation to cognitive abilities and 
systemic damage in systemic lupus erythematosus (SLE). 
Methods: Structural and diffusion magnetic resonance imaging (MRI) data were acquired from 
47 patients with SLE. Brains were segmented into 85 cortical and subcortical regions and 
combined with whole brain tractography to generate structural connectomes using graph 
theory. Global cognitive abilities were assessed using a composite variable g, derived from the 
first principal component of three common clinical screening tests of neurological function. 
SLE damage (LD) was measured using a composite of a validated SLE damage score and 
disease duration. Relationships between network connectivity metrics, cognitive ability and 
systemic damage were investigated. Hub nodes were identified. Multiple linear regression, 
adjusting for covariates, was employed to model the outcomes g and LD as a function of 
network metrics.  
Results: The network measures of density (standardised ß = 0.266, P = 0.025) and strength 
(standardised ß = 0.317, P = 0.022) were independently related to cognitive abilities. Strength 
(standardised ß = -0.330, P = 0.048), mean shortest path length (standardised ß = 0.401, P = 
0.020), global efficiency (standardised ß = -0.355, P = 0.041) and clustering coefficient 
(standardised ß = -0.378, P = 0.030) were independently related to systemic damage. Network 
metrics were not related to current disease activity.  
Conclusion: Better cognitive abilities and more SLE damage are related to brain topological 
network properties in this sample of SLE patients, even those without neuropsychiatric 
involvement and after correcting for important covariates. These data show that connectomics 
might be useful for understanding and monitoring cognitive function and white matter damage 
in SLE. 
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INTRODUCTION 
Mild cognitive impairments are common in systemic lupus erythematosus (SLE). The neural 
substrates are unknown which makes alleviating symptoms challenging. Understanding how 
brain structure correlates with the systemic damage caused since SLE diagnosis and its impact 
on cognitive abilities could help unravel an underlying mechanism and lead to better therapies. 
Damage to the physical brain white matter communication infrastructure could disrupt the 
coherence of structural networks resulting in impairments. Advanced brain imaging techniques 
could help identify asymptomatic brain damage associated with this disease. 
 
Connectomics1,2 uses graph theory3 to describe the brain as a network of anatomical links 
(edges) between brain cortical regions (nodes). Metrics of this topology, which broadly fall into 
two categories of integration and segregation, include path length and clustering. Shorter path 
lengths enhance network efficiency, while high clustering coefficients indicate a node’s 
neighbour is also well-connected to the rest of the network. The seemingly opposing properties 
of integration and segregation are characteristic of complex networks, like the human brain4. 
 
We recently5 showed an increase in cerebral small vessel disease (SVD) in a small sample of 
SLE patients which could account for these symptoms since SVD is a major cause of cognitive 
impairment and dementia6. Brain imaging features7 linked with SVD include white matter 
hyperintensities (WMH) which are thought to reflect late-stage (i.e., MRI-visible) white matter 
disease. Associations between cognitive abilities and biomarkers of brain microstructural 
integrity derived from diffusion magnetic resonance imaging (dMRI) were also found, but did 
not survive adjustment for covariates (age, disease duration, steroid use and an estimate of prior 
cognitive ability)8.  
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Here, the relationship between cognitive abilities, systemic damage caused by SLE and 
structural network metrics is investigated. We include both SLE and neuropsychiatric (NPSLE) 
patients, and not just NPSLE patients, as many SLE patients also complain of symptoms that 
could relate to early brain changes. An estimate of prior cognitive abilities and other covariates 
such as patients that were older, had greater volumes of cerebral disease on brain imaging and 
antiphospholipid status are adjusted for. Network hubs9 are identified and related to cognitive 
abilities and disease burden to examine whether associations were global or focal. This novel 
work is the first to use graph theory to model the brain’s structural connectivity in relation to 
cognition in SLE. 
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METHODS 
Subjects 
Consecutive patients seen by a consultant rheumatologist (E.N.A.) at a specialist SLE clinic 
between April and December 2014 were invited to join the study. From the 51 subjects that 
participated, 47 had available connectome and cognitive data for the present analysis. All 
patients met the updated American College of Rheumatology 1997 criteria for SLE10. The 
South East Scotland Research Ethics Committee gave study approval (01, 14/SS/0003), and all 
participants gave written consent.  
 
Cognitive assessments 
For pragmatism, current cognitive function was assessed with validated screening tools rather 
than a full neuropsychological battery, including the Montreal Cognitive Assessment 
(MoCA),11 Addenbrooke’s Cognitive Examination – Revised (ACER) 12 and Mini Mental State 
Examination (MMSE)13.  The National Adult Reading Test (NART)14 was used to adjust for 
premorbid intelligence. The NART is a validated15 estimate of premorbid intelligence as it 
appears broadly resilient to age-related cognitive decline.  
 
Disease activity 
Current SLE disease activity was assessed using the Systemic Lupus Erythematosus Disease 
Activity Index 2000 (SLEDAI-2K)16 and British Isles Lupus Assessment Group 2004 
(BILAG)17 tools. Accumulated permanent damage from SLE was assessed with the Systemic 
Lupus International Collaborating Clinics (SLICC)18,19 damage index.  
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Antiphospholipid status 
A definite diagnosis of antiphospholipid syndrome (APS) was made with consideration to the 
international consensus statement20. Blood markers of lupus anticoagulant and anticardiolipin 
antibodies (isotypes IgG and IgM) were collected as part of the study; historical blood results 
were also reviewed. 
 
MRI acquisition 
All MRI data were acquired using a GE Signa Horizon HDxt 1.5 T scanner (General Electric, 
Milwaukee, WI, USA) using a self-shielding gradient set with maximum gradient strength of 
33 mT m-1 and an 8-channel phased-array head coil. The scan protocol included axial T2-, 
gradient-recalled echo-, fluid-attenuated inversion recovery-, sagittal T2- and high-resolution 
coronal 3D T1-weighted volume sequences, and a whole brain dMRI acquisition. The dMRI 
protocol consisted of three T2-weighted and 32 diffusion-weighted (b=1000 s mm
-2) axial 
single-shot spin-echo echo-planar (EP) imaging volumes (field of view 240  240 mm, matrix 
128  128, TR 13.75 s and TE 78.4 ms). Each volume comprised 56 contiguous 2.5 mm thick 
axial slices with 1.875 mm in-plane resolution. Detailed scanning parameters have been 
published previoulsy8. 
 
Network metrics 
Detailed methods for image processing, tractography analysis, network construction and the 
identification of network hubs are given in Supplementary Material. For each resulting 
fractional anisotropy (FA)-weighted connectivity matrix in each patient, five global network 
measures, plus mean edge weight (mean FA for the network), were computed using the brain 
connectivity toolbox (https://sites.google.com/site/bctnet), namely, network density (fraction 
of present connections to all possible connections), strength (average sum of weights per node), 
6
LUP-17-130.R2 
mean shortest path length between nodes, global efficiency (average inverse shortest path 
length in the network) and clustering coefﬁcient (fraction of triangles around a node). Mean 
shortest path length is inversely related to the other connectivity metrics. 
 
Image review, visual rating and quantitative analysis 
All MRI scans were reviewed by a consultant neuroradiologist (J.M.W.) blind to all other data. 
Imaging features of SVD were defined per STRIVE guidelines.7 Deep and periventricular 
WMHs were coded 0 to 3 using the Fazekas21 scale. Intracranial (ICV), CSF, brain tissue (BTV) 
and WMH volumes were measured using Analyse 11.0 (http://analyzedirect.com) and in-house 
software ‘MCMxxxVI’, see http://sourceforge.net/projects/bric1936/?source=directory. These 
methods were developed locally and have been validated22,23. All segmented volumes were 
visually inspected for accuracy and to avoid erroneous classification. We corrected for head 
size by dividing the quantitative WMH volume by the ICV.  
 
Statistical analysis 
Data distributions were checked graphically for normality. Pearson’s correlation coefficient 
was used to assess the relationship between network connectivity measures and other variables. 
Principal components analysis was used to create two composite variables: cognitive ability (g) 
and SLE systemic damage (LD) (where g was derived from three cognitive test scores (MoCA, 
ACER and MMSE) and the first component explained 70% of variance; and LD was derived 
from the SLICC damage index plus disease duration and the first component explained 78% of 
variance). The connectivity measures were scaled (mean = 0, standard deviation = 1) and then 
used as explanatory variables in models using multiple linear regression with g and LD as 
outcomes of interest, controlling for age, disease duration, WMH volume, steroids, 
antiphospholipid status and NART. All analyses were conducted in R v3.3.0 (http://www.r-
project.org)24. Where there were multiple correlational comparisons, a threshold of P < 0.01 
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was used to denote significance (rather than adjustment for multiple testing which is often too 
conservative); importantly the P value is secondary to our primary interest being the magnitude 
of parameter estimates25,26, which include 95% confidence intervals.    
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RESULTS 
 
Subjects 
Forty-seven subjects of mean age 48.5 (SD 13.7, range 20 to 76) years had connectome data 
(Table 1). Less than one-fifth (17%) were hypertensive, none had diabetes, 12.7% were current 
smokers, and one subject had a history of stroke. One patient had incomplete cognitive data, 
two did not complete the NART test and three (6%) were being monitored for active NPSLE. 
Four patients were left-handed. 
 
Antiphospholipid status 
Seven subjects (14.9%) had a definitive diagnosis of APS, and in each case there were 
neurological and/or thrombus involvement (stroke, transient ischæmic attack, deep vein 
thrombosis, primary emboli and severe migraine).  Additionally, several other patients without 
a diagnosis of APS had one or more positive screens for lupus anticoagulant and raised 
anticardiolipin antibodies, and within these subjects further evidence of neurological 
involvement (aquaporin 4 antibodies, neurolupus, migraines, epilepsy, anxiety, depression and 
memory loss) was observed. 
 
Structural network connectivity and other variables 
The network metrics are highly correlated among each other (r values 0.54 to 0.99). Table 2 
shows associations between network metrics and other variables measured in this patient group. 
Mean shortest path length displayed relationships inverse to the other network metrics, as 
expected. 
 
Four of the network metrics (mean shortest path length (r = 0.32), global efficiency (r = -0.31), 
clustering coefficient (r = -0.33) and mean edge weight (r = -0.34)) were correlated with age. 
9
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All network metrics were inversely associated with disease duration (r values -0.31 to -0.39; 
mean shortest path length was positively correlated (r = 0.39)). All network metrics (bar 
network density) were inversely related to WMH volume (r values -0.41 to -0.54; mean shortest 
path length was positively correlated (r = 0.51)). All network metrics (bar mean edge weight, 
although even here the correlation coefficient was 0.28) were associated with g. All network 
metrics (bar density) were associated with SLICC. The two disease activity measures, SLEDAI 
and BILAG, were not related to network measures. 
 
Cognitive ability, SLE systemic damage and network measures globally 
The NART score correlated strongly with g (r = 0.69, P < 0.0001). The network measures 
density (standardised ß = 0.266, P = 0.025) and strength (standardised ß = 0.317, P = 0.022) 
were independently related to g in adjusted analyses (Table 3). All network connectivity 
measures were significantly associated with LD in unadjusted analyses. Strength (standardised 
ß = -0.330, P = 0.048), mean shortest path length (standardised ß = 0.401, P = 0.020), global 
efficiency (standardised ß = -0.355, P = 0.041) and clustering coefficient (standardised ß = -
0.378, P = 0.030) maintained independent relationships in adjusted analyses (Table 3).  
 
Network hubs, cognitive ability, SLE damage and network measures locally 
A total of 17 nodes were identified as network hubs (Figure 1). The nodes, as measured by 
nodal strength, which correlated most strongly with g included the right caudate (r = 0.55), left 
precentral (r = 0.50), left rostral middlefrontal (r = 0.41), and right lingual (r = 0.41) regions, 
although none of these were hub nodes (Figure 1). Some nodes had inverse relationships, 
including the right hippocampus (r = -0.32). 
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As indicated in Figure 1, the general finding was for weaker correlations between nodal strength 
and LD compared with g.  The nodes with the strongest relationships between nodal strength 
and LD included right superior parietal (r = -0.38), right caudate (r = -0.37), right rostral 
middlefrontal (r = -0.36), right pericalcarine (r = -0.36), right superior temporal (r = -0.32) 
right lateral occipital (r = -0.31), and left pericalcarine (r = -0.31) regions. A predilection for 
the right-side is noted. 
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DISCUSSION 
Cognitive abilities (g) were related to brain network topology such that poorer levels of 
segregation (indicated by clustering coefficient) as a marker for sub-network modularity, and 
integration (indicated by path length) as a marker for the connectedness of the brain, were 
associated with worse overall contemporaneous cognitive performance. Prior cognitive 
abilities, age and WMH volume are known to co-associate with current cognitive abilities yet 
the network measures remained independently related to current cognitive abilities in adjusted 
analyses that also corrected for antiphospholipid status. The network metrics did not associate 
with an estimate of prior cognitive ability.  
 
In a recent study of 80 patients with schizophrenia27, global connectivity predicted a global 
construct of general cognitive ability, but did not adjust for prior abilities. In our prior analysis8 
of the same cohort with quantitative tractography, better cognitive function was associated with 
lower levels of mean diffusivity as a biomarker for structurally intact white matter, but the 
relationship was confounded by age and an estimate of prior cognitive ability. Here, the 
relationship withstood adjustment, suggesting network measures could explain more variance 
in cognitive abilities than dMRI biomarkers measured in principle fibre tracts alone. Lawrence 
et al.28 similarly found associations with cognition were stronger for network measures than 
for other conventional dMRI metrics.  
 
Recently, an association between global network efficiency and cognitive performance in 436 
patients (mean age 65.2 years SD 8.8) with clinically evident SVD was reported29. A greater 
volume of WMH, number of lacunes and microbleeds correlated with reduced network density, 
strength, and global and local efficiency (correlation coefficients ranging from -0.19 to -0.62). 
Moreover, path analysis showed that network (in)efficiency might drive the association 
12
LUP-17-130.R2 
between SVD and cognitive ability. Another study28 found that 115 patients of mean age 70.2 
years (SD 9.7) with symptomatic SVD had reduced network efficiency versus age-matched 
healthy controls, and that global network efficiency related to worse performance on tests of 
processing speed, executive functioning, and gait velocity but not memory. 
 
The network metrics, bar density, showed an inverse association with WMH volume. Prior 
studies of older subjects with established clinically-evident SVD (N=436; age ~65 years)29, 
lacunar stroke (N=115; age ~70 years)28 and cerebral amyloid angiopathy (N=38; age ~69 
years)30 also found this association. Yet the present cohort are two decades younger and have 
a lower burden of visible SVD than those with established clinical SVD5, and so the relationship 
with network structure is noteworthy and could mean SVD-induced damage to the network is 
an early feature of SLE that accumulates to impact cognition, even in those without 
neuropsychiatric involvement. Network density is the fraction of present connections to 
possible connections. It is unclear why density has a weaker and non-significant relationship to 
WMH volume in our data, although connection weights are excluded from the calculation of 
density meaning the topology is represented without ‘adjustment’ for water molecule 
anisotropy which broadly represents the integrity of the connections rather than the number of 
connections per se. 
 
The systemic damage caused since SLE diagnosis (LD) was strongly inversely associated with 
network metrics in adjusted analyses, which included correcting for the most powerful 
predictor of damage – age.  The SLICC damage index and disease duration also related to LD 
when analysed separately (results from fully-adjusted linear models not shown). However, 
there was no relationship between structural network connectivity and current disease activity 
(SLEDAI or BILAG), a finding which contrasts with an fMRI study31 that found functional 
13
LUP-17-130.R2 
network connectivity was strongly correlated to SLEDAI score in 30 patients. The lack of 
association between disease activity and network measures, but association with permanent 
damage, could reflect the temporal relationship with inflammatory flares (as captured in the 
activity tools) which do not immediately translate into network damage but instead accumulate 
longitudinally. Studies that combine structural and functional network connectivity in SLE over 
time would be informative. 
 
In the current work, we also ranked nodes based on connectivity to the rest of the network and 
designated the top 20% by connectivity as network hubs. Network hubs were broadly similar 
to those identified in SLE patients by Xu et al32. The relationship between nodes and cognitive 
ability, and separately nodes and SLE systemic damage, did not have predilection for hub nodes 
but instead appeared distributed across the network.  
 
As with other connectome studies, the spatial scale of tractography and connectomics is several 
orders of magnitude larger than the underlying architecture of interest, namely axons (MRI 
voxels are roughly 1 or 2 mm3 versus microns for axon dimensions), such that the metrics here 
are only estimates of the ‘true’ neural pathways33. Additionally, the number and choice of nodes 
needs to be considered carefully as this can affect the connectivity output34 and there is no 
universally accepted cortical parcellation scheme35. We are unable to comment on how 
connectivity might change over time, nor comment on specific domains of cognitive ability 
such as memory and processing speed. We acknowledge that the cognitive tools used are not 
as sensitive as a full psychometric battery in detecting cognitive impairments, but they are 
routinely used as clinical screening tools and were chosen for pragmatism to be delivered within 
20 mins. We did not have access to data on dose of currently prescribed steroids, nor estimates 
of cumulative dosages or treatment duration so cannot comment on how these might affect the 
14
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connectome metrics. Finally, the lack of a control group is a limitation here, and could be 
addressed in future studies. 
 
The current study, the first to analyse brain structural networks and cognitive abilities in SLE, 
has shown that network metrics relate to disease duration, SLE-induced damage, WMH volume 
as a marker of SVD and cognitive abilities in this sample of patients. Patterns of connections 
derived from the science of connectomics could be used to assess and monitor the brain’s 
involvement in SLE, including treatment response. Further worthwhile research should assess 
the connectome-cognition relationship in SLE longitudinally. 
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Table 1: Subject characteristics. 
Demographics  
   N 47 
   Female (%) 43/47 (91.5%) 
   Age, years (SD; range) 
   Disease duration, months (Q1 to Q3) 
48.5 (13.7; 20 to 76) 
49 (24 to 118) 
   Steroids (currently prescribed) 17/47 (36%) 
   Diagnosed neuropsychiatric SLE 3/47 (6%) 
  
Vascular risk factors  
   Hypertension (%) 8/47 (17%) 
   Average systolic blood pressure, mmHg (SD) 126 (19.6) 
   Average diastolic blood pressure, mmHg (SD) 75 (13.7) 
   Diabetes (%) 0 (0%) 
   Current smoker (%) 6/47 (12.7%) 
   Total cholesterol, mmol/L (SD) 5/47 (0.98) 
   BMI, kg / m2 (SD) 28.9 (6.6) 
   History of stroke (%) 1/47 (2.1%) 
  
Antiphospholipid status  
   Diagnosed APS (%) 7/47 (14.9%) 
   Ever positive lupus anticoagulant screen (%) 11/47 (23.4%)  
   Anticardiolipin IgG (Q1 to Q3) 2.95 (1.97 to 5.32). Reference 0 to 13.3 
   Anticardiolipin IgM (Q1 to Q3) 1.65 (1.12 to 3.22). Reference 0 to 9.8 
  
Rheumatology scores  
   SLICC (Q1 to Q3) 0 (0 to 1) 
   SLEDAI (Q1 to Q3) 2 (0 to 4) 
   BILAG (Q1 to Q3) 1 (1 to 9) 
  
Cognitive ability  
   MoCA (Q1 to Q3) (n = 46) 26.5 (25 to 28). Max 30; normal ≥ 26  
   ACER (Q1 to Q3) (n = 46) 92.0 (88.2 to 94). Max 100; normal ≥ 88 
   MMSE (Q1 to Q3) (n = 46) 28.5 (27 to 30). Max 30; normal ≥ 27 
   NART (Q1 to Q3) (n = 45) 
 
34.0 (27 to 38)  
Fatigue, anxiety and depression  
   FSS (SD) 5.0 (1.7). Reference 2.3 (0.7); p < 0.0001 
   Anxiety (Q1 to Q3) 6.0 (3 to 12).  
   Depression (Q1 to Q3) 8.0 (6 to 12).  
  
Brain imaging   
   Brain tissue volume, ml (SD) 1171 (113) 
   WMH volume, ml (Q1 to Q3) 0.8 (0.4 to 1.9) 
   Total SVD score (Q1 to Q3) 1 (1 to 1). Possible range 0 to 4 
  
Network connectivity measures SLE                    
   Density (SD) 30.94 (1.05) 
   Strength (SD) 10.75 (0.63) 
   Mean shortest path length (SD) 4.10 (0.17)  
   Global efficiency (SD) 0.28 (0.01) 
   Clustering coefficient (SD) 0.28 (0.01) 
   Mean edge weight (SD) 0.41 (0.02) 
 
Values are mean (standard deviation), median (Q1 to Q3), or number (%). ACER = Addenbrooke’s Cognitive Examination – 
Revised, APS = antiphospholipid syndrome, BILAG = British Isle Lupus Assessment Group, BMI = body mass index, FSS = 
Fatigue Severity Scale, MoCA = Montreal Cognitive Assessment, MMSE = Mini Mental State Examination, NART = National 
Adult Reading Test, SLEDAI = Systemic Lupus Erythematosus Disease Activity Index, SLICC = Systemic Lupus International 
Collaborating Clinincs, SVD = small vessel disease, WMH = white matter hyperintensities.   
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Table 2: Relationship between network connectivity and other variables in SLE (N=47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are Pearson’s correlation coefficients (r). g and LD are composites of three measures of cognitive ability 
(MoCA + ACER + MMSE) and two measures of SLE damage (disease duration + SLICC), respectively 
(proportion of shared variance = 70% and 78% respectively). Bold indicates 95%CI does not pass through zero 
(i.e.P<0.05), however, owing to the large number of comparisons, a threshold of P<0.01 (denoted by *) is also 
highlighted to support the effect size estimate.  ACER = Addenbrooke’s Cognitive Examination – Revised, 
BILAG = British Isle Lupus Assessment Group, MoCA = Montreal Cognitive Assessment, MMSE = Mini Mental 
State Examination, NART = National Adult Reading Test, SLEDAI = Systemic Lupus Erythematosus Disease 
Activity Index, SLICC = Systemic Lupus International Collaborating Clinincs, WMH = white matter 
hyperintensities.  
  
 r  95%CI r  95%CI 
     
 Age WMH volume 
Density -0.12 -0.39 to 0.17 -0.12 -0.40 to 0.17 
Strength -0.28 -0.52 to 0.00 -0.41 -0.62 to -0.14 * 
Mean shortest path  0.32  0.03 to 0.55  0.51  0.26 to 0.69   * 
Global efficiency -0.31 -0.55 to -0.03 -0.50 -0.69 to -0.25 * 
Clustering coefficient -0.33 -0.56 to -0.04 -0.52 -0.70 to -0.27 * 
Mean edge weight -0.34 -0.57 to -0.06 -0.54 -0.72 to -0.30 * 
g -0.11 -0.39 to 0.18  0.00 -0.29 to 0.29 
LD  0.37  0.09 to 0.59 *  0.11 -0.18 to 0.38 
       
 SLICC Disease duration 
Density -0.23 -0.48 to 0.06 -0.35 -0.58 to -0.07 
Strength -0.34 -0.57 to -0.06 -0.39 -0.61 to -0.12 * 
Mean shortest path  0.39  0.11 to 0.61 *  0.39  0.12 to 0.61   * 
Global efficiency -0.35 -0.58 to -0.07 -0.36 -0.59 to -0.08 * 
Clustering coeficient -0.38 -0.60 to -0.10 * -0.37 -0.59 to -0.09 * 
Mean edge weight -0.33 -0.56 to -0.05 -0.31 -0.55 to -0.03 
g -0.34 -0.57 to -0.06 -0.37 -0.60 to -0.09 * 
LD  0.88  0.80 to 0.93 *  0.88  0.80 to 0.93   * 
       
 NART g 
Density  0.27 -0.02 to 0.52  0.48  0.22 to 0.67 * 
Strength  0.22 -0.08 to 0.48  0.45  0.18 to 0.65 * 
Mean shortest path -0.14 -0.42 to 0.15 -0.34 -0.57 to -0.06  
Global efficiency  0.15 -0.15 to 0.42  0.35  0.06 to 0.58 
Clustering coeficient  0.14 -0.16 to 0.41  0.32  0.04 to 0.56 
Mean edge weight  0.09 -0.20 to 0.38  0.28 -0.01 to 0.52 
g  0.69  0.50 to 0.82 *  -- ---- 
LD -0.21 -0.48 to 0.08 -0.40 -0.62 to -0.13 * 
       
 SLEDAI BILAG 
Density -0.13 -0.40 to 0.16 -0.12 -0.39 to 0.17 
Strength -0.07 -0.35 to 0.22 -0.06 -0.34 to 0.22 
Mean shortest path  0.04 -0.25 to 0.32  0.01 -0.29 to 0.28 
Global efficiency -0.02 -0.30 to 0.27 -0.01 -0.28 to 0.29 
Clustering coeficient -0.02 -0.31 to 0.26 -0.03 -0.32 to 0.25 
Mean edge weight  0.01 -0.27 to 0.30  0.02 -0.26 to 0.31 
g -0.05 -0.33 to 0.24 -0.07 -0.36 to 0.22 
LD -0.03 -0.32 to 0.25  0.00 -0.28 to 0.28 
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Table 3: Multiple linear regression showing relationship between cognitive abilities (g), SLE 
systemic damage (LD) and brain network connectivity in SLE (N=47). 
 
 ß  SE ß  P value ß  SE ß  P value 
 Unadjusted Adjusted* 
Relationship to cognitive abilities (g): 
Density  0.490 0.136 0.001  0.266 0.114 0.025 
Strength  0.474 0.141 0.001  0.317 0.133 0.022 
Mean shortest path -0.355 0.146 0.019 -0.242 0.146 0.106 
Global efficiency  0.364 0.147 0.017  0.249 0.143 0.090 
Clustering coefficient  0.333 0.147 0.028  0.207 0.146 0.164 
Mean edge weight  0.285 0.148 0.062  0.191 0.145 0.196 
       
Relationship to SLE damage (LD): 
Density -0.326 0.141 0.025 -0.210 0.145 0.155 
Strength -0.414 0.136 0.004 -0.330 0.162 0.048 
Mean shortest path  0.444 0.133 0.001  0.401 0.165 0.020 
Global efficiency -0.406 0.136 0.004 -0.355 0.168 0.041 
Clustering coefficient -0.423 0.135 0.003 -0.378 0.167 0.030 
Mean edge weight -0.365 0.139 0.011 -0.306 0.173 0.084 
 
ß = standardised beta. * Adjusted for age, WMH volume, steroids, NART, diagnosed APS and ever positive lupus 
anti-cogaulant. g is a composite (MoCA + ACER + MMSE). LD is a composite (disease duration + SLICC). The 
relationship with g was also adjusted for disease duration. ACER = Addenbrooke’s Cognitive Examination – 
Revised, APS = antiphospholipid syndrome, MoCA = Montreal Cognitive Assessment, MMSE = Mini Mental 
State Examination, NART = National Adult Reading Test, SLICC = Systemic Lupus International Collaborating 
Clinincs, WMH = white matter hyperintensities. Note: The individual network connectivity measures as predictor 
variables are not modelled together in one large model due to multicolinearity between connectivity variables, 
instead each individual row is a separate regression model. 
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Figure 1: The relationship between nodal strength and the composite score for cognitive ability 
(g) for left and right side of the brain; there is a tendency for positive associations, such that 
greater cognitive ability correlates with higher nodal strength. Significant correlations are 
indicated, while blank entries represent non-significant r values. Also shown, the relationship 
between nodal strength and lupus damage (LD); here there is a tendency for negative 
associations, such that greater lupus damage correlates with worse connectivity. Graphic is 
ordered top to bottom by ‘nodal connectivity’ derived from betweeness centrality and degree, 
with the top 20% of nodes (first 17 nodes listed) designated as network hubs. Deep grey matter 
structures are also noted. 
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